Identification of melanoma-specific serological markers using proteomic analyses

Proteomics - Clinical Applications

Volumn 3, Issue 5, 2009, Pages 552-562

  Takikawa, Masako ^a   Akiyama, Yasuto ^a   Ashizawa, Tadashi ^a   Yamamoto, Akifumi ^b   Yamazaki, Naoya ^c   Kiyohara, Yoshio ^a   Oku, Naoto ^d   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Chemokine; Metastatic melanoma; Nano LC MS MS; Plasma marker; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; DENDRITIC CELL VACCINE; INTER ALPHA TRYPSIN INHIBITOR; MESSENGER RNA; PROPLATELET BASIC PROTEIN PRECURSOR; PROTEIN PRECURSOR; SERUM AMYLOID A; SERUM AMYLOID A2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOCYTE; MELANOMA; METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; SEROLOGY; SURVIVAL TIME; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 67649435605     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200800165     Document Type: Article

References (32)

1. Wimmer, I., Meyer, J. C., Seifert, B., Dummer, R. et al., Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 1997, 57, 5073-5076.
2. Wakamatsu, K., Kageshita, T., Furue, M., Hatta, N. et al., Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years'experience. Melanoma Res. 2002, 12, 245-253.
3. Bosserhoff, A. K., Kaufmann, M., Kaluza, B., Bartke, I. et al., Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997, 57, 3149-3153.
4. Brochez, L., Naeyaert, J. M., Serological markers for melanoma. Br. J. Dermatol. 2000, 143, 256-268.
5. Zhang, Z., Bast, R. C. Jr, Yu, Y., Li, J. et al., Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004, 64, 5882-5890.
6. Honda, K., Hayashida, Y., Umaki, T., Okusaka, T. et al., Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005, 65, 10613-10622.
7. Yang, Z., Harris, L. E., Palmer-Toy, D. E., Hancock, W. S. et al., Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin. Chemistry 2006, 52, 1897-1905.
8. Lam, Y. W., Mobley, J. A., Evans, J. E., Carmody, J. F. et al., Mass profilling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics 2005, 5, 2927-2938.
9. Wilson, L. L., Tran, L., Morton, D. L., Hoon, D. S., Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry. Ann. NY Acad. Sci. 2004, 1022, 317-322.
10. Caputo, E., Lombardi, M. L., Lunongo, V., Moharram, R. et al., Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005, 819, 59-66.
11. Mian, S., Ugurel, S., Parkinson, E., Schlenzka, I. et al., Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 2005, 23, 5088-5093.
12. Akiyama, Y., Tanosaki, R., Inoue, N., Shimada, M. et al., Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J. Transl. Med. 2005, 3, 4.
13. Akiyama, Y., Maruyama, K., Nara, N., Mochizuki, T. et al., Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail. Anticancer Res. 2004, 24, 571-578.
14. Estaller, C., Schwaeble, W., Dierich, M., Weiss, E. H., Human complement factor H: two factor H proteins are derived from alternatively spliced transcripts. Eur. J. Immunol. 1991, 21, 799-802.
15. Meyer, T., Hauschild, A., Kromminga, A., Hartleb, J. et al., Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumor marker for malignant melanoma. Melanoma Res. 2002, 12, 471-477.
16. Menzies, S. W., Kreusch, J., Byth, K., Pizzichetta, M. A. et al., Dermascopic evaluation of amelanotic and hypomelanotic melanoma. Arch. Dermatol. 2008, 144, 1120-1127.
17. Strieter, R.M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A. et al., The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 1995, 270, 27348-27357.
18. Smith, D. R., Polverini, P. J., Kunkel, S. L., Orringer, M. B. et al., Inhibition of IL-8 attenuates angiogenesis in bronchogenic carcinoma. J. Exp. Med. 1994, 179, 1409-1415.
19. Arenberg, D. A., Kunkel, S. L., Polverini, P. J., Glass, M., et al., Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCIDmice. J. Clin. Invest. 1996, 97, 2792-2802.
20. Haghnegahdar, H., Du, J., Wang, D., Strieter, R. M. et al., The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J. Leukoc. Biol. 2000, 67, 53-62.
21. Luan, J., Shattuck-Brandt, R., Haghnegahdar, H., Owen, J. D. et al., Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukoc. Biol. 1997, 62, 588-597.
22. Toulza, F., Eliaou, J. F., Pinet, V., Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines. Int. J. Cancer 2005, 115, 429-436.
23. Longo-Imedio, M. I., Longo, N., Trevino, I., Lazaro, P. et al., Clinical significance of CXCR3 and CXCR4 expression in primary melanoma. Int. J. Cancer 2005, 117, 861-865.
24. Scala, S., Ottaiano, A., Ascierto, P. A., Gavalli, M. et al., Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin. Cancer Res. 2005, 11, 1835-1841.
25. Banfalvi, T., Boldizsar, M., Gergye, M., Gilde, K. et al., Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma. Pathol. Oncol. Res. 2002, 8, 183-187.
26. Khan, N., Cromer, C. J., Campa, M., Patz, E. F. Jr., Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. Cancer 2004, 101, 379-384.
27. Cho, W. C., Yip, T. T., Yip, C., Yip, V. et al., Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin. Cancer Res. 2004, 10, 43-52.
28. Raitanen, M. P., Marttila, T., Kaasinen, E., Rintala, E. et al., Sensitivity of human complement factor H related protein (BTA stat) test and voided urine cytology in the diagnosis of bladder cancer. J. Urol. 2000, 163, 1689-1692.
29. Junnikkala, S., Jokiranta, T. S., Friese, M. A., Jarva, H. et al., Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-Like protein 1. J. Immunol. 2000, 164, 6075-6081.
30. Junnikkala, S., Hakulinen, J., Jarva, H., Manuelian, T. et al., Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br. J. Cancer 2002, 87, 1119-1127.
31. Cho, W. C., Yip, T. T., Ngan, R. K., Yip, T. T. et al., ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin. Chem. 2007, 53, 241-250.
32. Yu, K. H., Rustgi, A. K., Blair, I. A., Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 2005, 4, 1742-1751.